Re-programing Chromatin with a Bifunctional LSD1/HDAC Inhibitor Induces Therapeutic Differentiation in DIPG.

Journal: Cancer Cell

Published: 2019-10-16

DOI: 10.1016/j.ccell.2019.09.005

Affiliations: 19

Authors: 21

Go to article
Institutions Share
Department of Dermatology, BU, United States of America (USA) 0.14
Lurie Family Imaging Center (LFIC), DFCI, United States of America (USA) 0.10
Division of Neonatology (Newborn Medicine), BCH, United States of America (USA) 0.07
Broad Institute of MIT and Harvard, United States of America (USA) 0.07
Harvard Department of Cell Biology, United States of America (USA) 0.07
NYU Robert I. Grossman School of Medicine, United States of America (USA) 0.05
Duke University, United States of America (USA) 0.05
Dana-Farber/Boston Children's Cancer and Blood Disorders Center, United States of America (USA) 0.05
Department of Biomedical Sciences, Penn Vet, United States of America (USA) 0.05
Sanofi Pasteur, United States of America (USA) 0.05
Division of Genetics, BWH, United States of America (USA) 0.05
Harvard Department of Biological Chemistry and Molecular Pharmacology (BCMP), United States of America (USA) 0.05
UNC Eshelman School of Pharmacy, United States of America (USA) 0.05
Harvard Medical School (HMS), United States of America (USA) 0.04
Department of Pathology, MGH, United States of America (USA) 0.04
Center for Cancer Research, MGH, United States of America (USA) 0.04
MIT David H. Koch Institute for Integrative Cancer Research, United States of America (USA) 0.02
Department of Pathology, BCH, United States of America (USA) 0.02
Howard Hughes Medical Institute (HHMI), United States of America (USA) 0

Return

Except where otherwise noted © 2021 Springer Nature Limited. All Rights Reserved.
partner of AGORA, HINARI, OARE, INASP, ORCID, CrossRef and COUNTER